ADAP Stock Overview
A commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$1.48 |
| 52 Week Low | US$0.20 |
| Beta | 2.85 |
| 1 Month Change | 16.67% |
| 3 Month Change | -51.92% |
| 1 Year Change | -74.96% |
| 3 Year Change | -83.05% |
| 5 Year Change | -95.18% |
| Change since IPO | -98.39% |
Recent News & Updates
Recent updates
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Apr 04 Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Mar 11
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
Jan 01Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Dec 15Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Shareholder Returns
| ADAP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | 3.7% | 5.3% |
| 1Y | -75.0% | -14.5% | 11.9% |
Return vs Industry: ADAP underperformed the US Biotechs industry which returned -14.5% over the past year.
Return vs Market: ADAP underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ADAP volatility | |
|---|---|
| ADAP Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ADAP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADAP's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 506 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Adaptimmune Therapeutics plc Fundamentals Summary
| ADAP fundamental statistics | |
|---|---|
| Market cap | US$73.34m |
| Earnings (TTM) | -US$69.89m |
| Revenue (TTM) | US$179.64m |
0.4x
P/S Ratio-1.0x
P/E RatioIs ADAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADAP income statement (TTM) | |
|---|---|
| Revenue | US$179.64m |
| Cost of Revenue | US$150.01m |
| Gross Profit | US$29.63m |
| Other Expenses | US$99.53m |
| Earnings | -US$69.89m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 16.49% |
| Net Profit Margin | -38.91% |
| Debt/Equity Ratio | -67.9% |
How did ADAP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 02:37 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adaptimmune Therapeutics plc is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Ying Huang | BofA Global Research |
| Olga Smolentseva | Bryan Garnier & Co |